Claims for Patent: 9,828,399
✉ Email this page to a colleague
Summary for Patent: 9,828,399
Title: | TC-PTP inhibitors as APC activators for immunotherapy |
Abstract: | The invention encompasses the novel class of compounds represented by the Formula (I) below, which are inhibitors of the TC-PTP enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown above and methods of treating or preventing TC-PTP mediated diseases, including cancer, via their use in the activation of antigen-presenting cells, like dendritic cells, for applications in the immunotherapeutic treatment of diseases. ##STR00001## |
Inventor(s): | Tremblay; Michel L. (Montreal, CA), Penafuerte; Claudia (Montreal, CA), Feldhammer; Matthew (Montreal, CA), Zogopoulos; George (Montreal, CA), Black; Cameron (Baie d\'Urfe, CA), Kennedy; Brian (Kirkland, CA) |
Assignee: | The Royal Institution For The Advancement Of Learning/McGill University (Montreal, CA) |
Application Number: | 15/122,031 |
Patent Claims: | 1. A compound of structural Formula Ib, or a pharmaceutically acceptable salts thereof, and stereoisomers thereof: ##STR00031## wherein: R.sup.1 is selected from the
group consisting of (a) C.sub.1-3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from --OH, --OC.sub.1-3 alkyl optionally substituted with 1-3 halogens, and --CN; (b) --(C.dbd.O)R.sup.4; (c) --CN; (d)
--(C.dbd.O)OR.sup.4; (e) --(C.dbd.O)NHR.sup.4; and (f) --(C.dbd.O)NR.sup.5R.sup.6; R.sup.4 is selected from the group consisting of (a) H; and (b) C.sub.1-3 alkyl optionally substituted with 1-5 halogens and; R.sup.5 and R.sup.6 are independently
selected from the group consisting of C.sub.1-3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from --OH, and --OC.sub.1-3 alkyl optionally substituted with 1-3 halogens.
2. The compound of Formula Ib as defined in claim 1, or a pharmaceutically acceptable salt thereof, selected from the following compounds: ##STR00032## 3. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 4. A pharmaceutical composition according to claim 3, further comprising one or more additional compounds selected from the group consisting of: (a) a cytotoxic agent; (b) an antimetabolite; (c) an alkylating agent; (d) an anthracycline; (e) an antibiotic; (f) an anti-mitotic agent; (g) an hormone therapy; (h) a signal transduction inhibitor; (i) a gene expression modulator; (j) an apoptosis inducer; (k) an angiogenesis inhibitor; and (l) an immunotherapy agent. 5. The pharmaceutical composition of claim 4, wherein said cytotoxic agent is taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, analogs or homologs thereof, or a combination thereof; wherein said antimetabolites is methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine, or a combination thereof; wherein said alkylating agent is mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU), lomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, cis-dichlorodiamine platinum (II) (DDP) cisplatin, or a combination thereof; wherein said anthracycline is daunorubicin, doxorubicin, or a combination thereof; wherein said antibiotic is dactinomycin, bleomycin, mithramycin, anthramycin (AMC), or a combination thereof; wherein said anti-mitotic agent is vincristine, vinblastine, or a combination thereof; wherein said signal transduction inhibitor is imatinib, trastuzumab, or a combination thereof; wherein said gene expression modulator is a siRNA, a shRNA, an antisense oligonucleotide, an HDAC inhibitor, or a combination thereof; wherein said immunotherapy agent is a monoclonal antibody, a chimeric antigen receptors (CARs) -T-Cell, or a combination thereof; wherein said hormone therapy is an luteinizing hormone-releasing hormone (LHRH) antagonist; wherein said apoptosis inducers is a recombinant human TNF-related apoptosis-inducing ligand (TRAIL); wherein said angiogenesis inhibitors is sorafenib, sunitinib, pazopanib, everolimus or a combination thereof. 6. The pharmaceutical composition of claim 5, wherein said monoclonal antibody is anti-CTLA4, anti-PD1 or a combination thereof. |
Details for Patent 9,828,399
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2034-02-28 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2034-02-28 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2034-02-28 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.